A5059700027- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Electrostatic Discharge in Electronics
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
University of Zurich
2022-2023
Life Science Zurich
2023
Though the effect of recently identified mitochondrial NAD+ transporter SLC25A51 on glucose metabolism has been described, its contribution to other NAD+-dependent processes throughout cell such as ADP-ribosylation remains elusive. Here, we report that absence leads increased concentration not only in cytoplasm and but also nucleus. The increase is associated with upregulation salvage pathway, implying an accumulation constitutively synthesized This results PARP1-mediated nuclear...
Myelofibrosis is a hematopoietic stem cell disorder belonging to the myeloproliferative neoplasms. patients frequently carry driver mutations in either JAK2 or Calreticulin (CALR) and have limited therapeutic options. Here, we integrate ex vivo drug response proteotype analyses across myelofibrosis patient cohorts discover targetable vulnerabilities associated strategies. Drug sensitivities of mutated progenitor cells were measured blood using high-content imaging single-cell deep...
Background: Myeloproliferative neoplasms (MPN) are a family of hematopoietic stem cell diseases characterized by frequent driver mutations in Calreticulin (CALR) and JAK2. While patients with essential thrombocythemia (ET) have more favorable outcome, the prognosis advanced myelofibrosis (MF) is particularly poor limited therapeutic options. Aims: Here, we set out to elucidate biology underlying MPN translate this into vulnerabilities that can be exploited targeted therapies. By integration...